# US 2022/0033383 A1 · Functionalized peptides as antiviral agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033383 A1
- Document ID: US20220033383A1
- Status: Published application
- Kind: A1
- Application number: 17/379,409
- Filed: 2021-07-19
- Published: 2022-02-03
- Earliest claimed: 2020-07-20
- Assignees: Enanta Pharmaceuticals, Inc.
- Applicants: Enanta Pharmaceuticals, Inc.
- Inventors: Joseph D. Panarese; Dexter Davis; Nathaniel Thomas Kenton; Samuel Bartlett; Sean M. Rafferty; Yat Sun Or
- Web page: https://patentgrep.com/patent/US20220033383A1

## CPC

- C07D 403/14: containing three or more hetero rings
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61P 31/14: for RNA viruses
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07K 5/0202: {containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids}
- C07K 5/06139: {with the first amino acid being heterocyclic}
- C07K 5/06165: {and Pro-amino acid; Derivatives thereof}
- C07K 5/0823: {and Pro-amino acid; Derivatives thereof}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound represented by Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
A is selected from:
1) Optionally substituted —C1-C8 alkyl;
2) Optionally substituted —C3-C12 cycloalkyl;
3) Optionally substituted 3- to 12-membered heterocycloalkyl;
4) Optionally substituted aryl; and
5) Optionally substituted heteroaryl;
L1 is —C(R11R12)—;
L2 is —C(R11R12)—;
n1 is 0, 1, 2, 3, or 4;
X is optionally substituted —C1-C6 alkyl, —CN, —C(O)R15, —C(O)NR13R14, or —C(O)C(O)NR13R14;
Q is —C(R11′R12′)—;
n2 is 0, 1, 2, 3, or 4;
Each R11, R11′, R12, and R12′ are each independently selected from:
1) Hydrogen;
2) Halogen;
3) —OR16;
4) —SR16;
5) —NR13R14;
6) —OC(O)NR13R14;
7) Optionally substituted —C1-C6 alkyl;
8) Optionally substituted —C3-C8 cycloalkyl;
9) Optionally substituted 3- to 8-membered heterocycloalkyl;
10) Optionally substituted aryl; and
11) Optionally substituted heteroaryl;
alternatively, R11 and R12 are taken together with the carbon atom to which they are attached to form an optionally substituted 3- to 8-membered carbocyclic or heterocyclic ring;
alternatively, when n1 is not 0, two adjacent Ru groups are taken together with the carbon atoms to which they are attached to form an optionally substituted 3- to 8-membered carbocyclic or heterocyclic ring;
alternatively, n1 is 2, 3 or 4, and the Ru groups on two non-adjacent carbon atoms are taken together with the carbon atoms to which they are attached to form an optionally substituted bridging moiety;
R13 and R14 are each independently selected from:
1) Hydrogen;
2) Optionally substituted —C1-C6 alkyl;
3) Optionally substituted —C3-C8 cycloalkyl;
4) Optionally substituted 3- to 8-membered heterocycloalkyl;
5) Optionally substituted aryl;
6) Optionally substituted arylalkyl;
7) Optionally substituted heteroaryl;
8) Optionally substituted heteroarylalkyl;
9) —C(O)R15;
10) —S(O)2R16; and
11) —NH2;
alternatively, R13 and R14 are taken together with the nitrogen atom to which they are attached to form an optionally substituted 3- to 8-membered heterocyclic ring;
R15 is selected from:
1) Hydrogen;
2) Halogen;
3) —OH;
4) Optionally substituted —C1-C6 alkyl;
5) Optionally substituted —C1-C6 alkoxy;
6) Optionally substituted —C3-C8 cycloalkyl;
7) Optionally substituted 3- to 8-membered heterocycloalkyl;
8) Optionally substituted aryl;
9) Optionally substituted arylalkyl;
10) Optionally substituted heteroaryl; and
11) Optionally substituted heteroarylalkyl;
R16 is selected from:
1) Hydrogen;
2) —OH;
3) Optionally substituted —C1-C6 alkyl;
4) Optionally substituted —C3-C8 cycloalkyl;
5) Optionally substituted 3- to 8-membered heterocycloalkyl;
6) Optionally substituted aryl;
7) Optionally substituted arylalkyl;
8) Optionally substituted heteroaryl, and
9) Optionally substituted heteroarylalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A is derived from one of the following, and optionally substituted:

### Claim 3 (depends on 1)

The compound of claim 1, wherein A is —C(NR13R14)R24R25, wherein R24 is hydrogen, halogen, optionally substituted —C1-C6 alkyl, optionally substituted —C1-C6 alkoxy, optionally substituted —C3-C12 cycloalkyl, optionally substituted 3- to 12-membered heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R25 is hydrogen or halogen; and R13 and R14 are as defined in claim 1.

### Claim 4 (depends on 1)

The compound of claim 1, wherein X is —CN, —C(O)CH2OC(O)R21, —C(O)CH2C(O)2R21, —C(O)CH2OR21, —C(O)CH2R22, —C(O)C(O)NHR21, —C(O)R21, —CHR21OC(O)R21, —CHR21C(O)2R21, —CHR21(OR21), or —CH(OR21)2, R21 is hydrogen, optionally substituted —C1-C6 alkyl, optionally substituted —C3-C8 cycloalkyl, optionally substituted 3- to 8-membered heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and R22 is halogen, or —NR13R14, and R13 and R14 are as defined in claim 1.

### Claim 5 (depends on 1)

The compound of claim 1, represented by one of Formulas (IV-1) to (IV-4), or a pharmaceutically acceptable salt thereof:
wherein R17 is halogen, —OR16, —SR16; —NR13R14; —OC(O)NR13R14; optionally substituted —C1-C6 alkyl; optionally substituted —C3-C8 cycloalkyl; optionally substituted 3- to 8-membered heterocycloalkyl; optionally substituted aryl; or optionally substituted heteroaryl; m1 is 0, 1, 2, or 3; m2 is 0, 1, 2, 3, or 4; A, R11, R11′, and X are as defined in claim 1.

### Claim 6 (depends on 1)

The compound of claim 1, represented by one of Formula (V-1), Formula (V-2), Formula (V-3), or Formula (V-4), or a pharmaceutically acceptable salt thereof:
wherein each T is CR11; each U is —C(R11R12)—; each V is —O—, —S—, —C(R11R12)—, or —N(R13R14)—; m is 0, 1 or 2; m′ is 0, 1, 2, or 3; and A, Q, n2, Ru, R12, R13, R14, and X are as defined in claim 1.

### Claim 7 (depends on 1)

The compound of claim 1, represented by one of Formulas (VI-1a) to (VI-8a), or a pharmaceutically acceptable salt thereof:
wherein X and A are as defined in claim 1.

### Claim 8 (depends on 1)

The compound of claim 1, represented by one of Formulas (IX-1) to (IX-8), or a pharmaceutically acceptable salt thereof:
wherein R32 is hydrogen, —F, C1, —CH3, —CF3 or —OR; R33 is —Cl, —Br, —OR21, —NHR21, or —OC(O)R21; R34 is R21; R21 is hydrogen, optionally substituted —C1-C6 alkyl, optionally substituted —C3-C8 cycloalkyl, optionally substituted 3- to 8-membered heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and A are as defined in claim 1.

### Claim 9 (depends on 1)

The compound of claim 1, represented by one of Formulas (IX-1) to (IX-8), or a pharmaceutically acceptable salt thereof:
wherein R24 is hydrogen, halogen, optionally substituted —C1-C6 alkyl, optionally substituted —C1-C6 alkoxy, optionally substituted —C3-C12 cycloalkyl, optionally substituted 3- to 12-membered heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R25 is hydrogen or halogen; and X, R13 and R14 are as defined in claim 1.

### Claim 10 (depends on 1)

The compound of claim 1, represented by one of Formulas (XIII-1) to (XIII-4), or a pharmaceutically acceptable salt thereof:
wherein R24 is hydrogen, halogen, optionally substituted —C1-C6 alkyl, optionally substituted —C1-C6 alkoxy, optionally substituted —C3-C12 cycloalkyl, optionally substituted 3- to 12-membered heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; and R15 and X are as defined in claim 1.

### Claim 11 (depends on 1)

The compound of claim 1, selected from the compounds set forth below or a pharmaceutically acceptable salt thereof:
Compound
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 13 (depends on 1)

A method of treating or preventing a virus infection, including a virus infection from an RNA-based virus, a coronavirus, a rhinovirus and a norovirus, in a subject susceptible to or suffering from the virus infection, the method comprising administering to the subject an inhibitor of a 3C protease enzyme wherein the inhibitor is a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A method of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a combination of compounds according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 13)

A method according to claim 13, wherein the virus is a coronavirus selected from a 229E, NL63, OC43, HKU1, SARS-CoV or a MERS coronavirus.

### Claim 16 (depends on 1)

A method of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject an inhibitor of a 3C protease enzyme wherein the inhibitor comprises a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A method of inhibiting viral 3C protease or viral 3CL protease in a mammal, comprising administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the subject is a human.

### Claim 19 (depends on 1)

A method of treating a respiratory disorder, including acute asthma, lung disease secondary to environmental exposures, acute lung infection, chronic lung infection, in a subject in need thereof, comprising administering to the subject a compound of claim 1.

### Claim 20 (depends on 19)

The method according to claim 19 wherein the compound or pharmaceutical composition is administered orally, subcutaneously, intravenously or by inhalation.
